Vertex Pharmaceuticals Inc

2026. g. 13. aug. 23:26 UTC

Vertex Pharmaceuticals shares are higher in after-market hours, following a modest decline earlier. The stock remains above its 20-day moving average.

2026. g. 12. aug. 19:42 UTC

Vertex Pharmaceuticals is trading lower today, pulling back from an earlier session high. No specific news has been identified to explain the decline.

2026. g. 11. aug. 19:36 UTC

Vertex Pharmaceuticals gained today after Bank of America Merrill Lynch added it to the US 1 List, reflecting strong confidence in its future prospects.

2026. g. 10. aug. 20:02 UTC

Vertex Pharmaceuticals shares rose following Sionna Therapeutics' trial failure, easing competitive pressure on Trikafta. BMO analyst noted this as a positive for Vertex's franchise.

2026. g. 7. aug. 19:51 UTC

Vertex Pharmaceuticals shares are higher as the Biotechnology sector strengthens. The company reported $3.33 billion in second-quarter revenue, driven by cystic fibrosis sales.

2026. g. 6. aug. 19:26 UTC

Vertex Pharmaceuticals is trading near unchanged levels with no specific news identified. The stock remains within a narrow range today.

2026. g. 5. aug. 19:16 UTC

Vertex Pharmaceuticals shares are higher as Barclays raises its price target to $617. Truist maintains a Buy rating and sets a target of $565.

2026. g. 4. aug. 20:05 UTC

Vertex Pharmaceuticals is rising today, buoyed by analyst upgrades and a strong Q2 revenue of $3.33 billion, with TD Cowen raising its target to $550.

2026. g. 3. aug. 23:26 UTC

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

2026. g. 31. jūl. 19:56 UTC

Vertex Pharmaceuticals is trading lower amid broader market trends, despite its $10 billion acquisition of Crinetics Pharmaceuticals still pending closure.

2026. g. 30. jūl. 23:26 UTC

Vertex Pharmaceuticals shares are lower in after-market hours, following a notable dip earlier in the session. No specific news was identified to explain the decline.

2026. g. 29. jūl. 23:36 UTC

Vertex Pharmaceuticals Inc shares are higher in after-market trading, recovering from an earlier dip. The stock shows notable volatility within its recent trading range.

2026. g. 28. jūl. 15:22 UTC

Vertex Pharmaceuticals Inc. shares are higher as biotechnology stocks advance. This follows a recent trend of higher daily closes since Monday's close.

2026. g. 27. jūl. 19:51 UTC

Vertex Pharmaceuticals is gaining modestly today amid broader market volatility and a significant decline in crude oil prices affecting overall sentiment.

2026. g. 24. jūl. 13:46 UTC

Vertex Pharmaceuticals is experiencing modest gains amid broader market sentiment influenced by a drop in initial jobless claims to a near 54-year low.

2026. g. 22. jūl. 20:06 UTC

Vertex Pharmaceuticals is lower amid market volatility and uncertainty ahead of the Federal Reserve meeting, reflecting a cumulative decline since Tuesday's close.

2026. g. 20. jūl. 18:41 UTC

Vertex Pharmaceuticals shares are lower amid a broader decline in the Biotechnology sector. The company recently completed a $10 billion acquisition to enhance its portfolio.

2026. g. 17. jūl. 18:56 UTC

Vertex Pharmaceuticals shares are declining amid broader market pressures from rising oil prices and inflation concerns linked to military actions in the Gulf region.

2026. g. 16. jūl. 19:51 UTC

Biotechnology stocks are advancing, supporting Vertex Pharmaceuticals' upward movement. This marks a shift from the recent trend of higher daily closes.

2026. g. 15. jūl. 18:36 UTC

Vertex Pharmaceuticals agrees to acquire Crinetics Pharmaceuticals for $85 per share. Shares are higher as analysts view the deal positively amid easing inflation pressures.

2026. g. 14. jūl. 23:16 UTC

Vertex Pharmaceuticals Inc shares are trading lower in after-market hours, continuing a trend of six consecutive daily declines without any specific news to explain the movement.

2026. g. 13. jūl. 19:06 UTC

Vertex Pharmaceuticals announced an agreement to acquire Crinetics for $85 per share, valued at $10 billion, while shares are lower during Monday's session.

2026. g. 10. jūl. 20:02 UTC

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

2026. g. 9. jūl. 23:16 UTC

Vertex Pharmaceuticals shares are lower in after-market trading, with no specific news identified to explain the movement amid broader market sentiment influenced by U.S.-Iran tensions.

2026. g. 8. jūl. 23:46 UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite significant declines in European markets amid geopolitical tensions involving the U.S. and Iran.

2026. g. 7. jūl. 19:36 UTC

Vertex Pharmaceuticals shares are lower today following its $10 billion acquisition of Crinetics Pharmaceuticals, despite analyst support and price target increases.

2026. g. 6. jūl. 23:02 UTC

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

2026. g. 2. jūl. 20:03 UTC

Vertex Pharmaceuticals shares are higher following FDA approval for expanded use of CASGEVY, now available for children as young as 2 years old.

2026. g. 1. jūl. 20:06 UTC

Vertex Pharmaceuticals shares are advancing, reflecting broader market trends. The stock remains above its 20-day moving average despite an earlier session pullback.

2026. g. 30. jūn. 20:07 UTC

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.